Kansas Biosciences Authority Funded Projects
Efficacy of different vectors–based CSFV and PEDV vaccines in pigs
Kansas State University PI: Wenjun Ma
Kansas State University Co-PI: Zhilong Yang
Kansas State University Co-PI: Juergen Richt
Icahn School of Medicine Co-PI: Adolfo Garcia-Sastre
01/01/2016 – 12/31/2016
Abstract:
The goal of this project is to evaluate efficacy of two vectored vaccines (Newcastle Disease Virus-vectored and vaccinia virus-vectored vaccines) for porcine epidemic diarrhea (PED) and classical swine fever (CSF). This project includes 3 specific objectives: 1) Determine immunogenicity and immunization approach (prime/boost) using vaccinia virus (VACV)-vectored and Virus (NDV)-vectored PED vaccines in pigs; 2) Evaluate efficacy of the optimized approach using NDV-vectored and VACV-vectored PED vaccines in pregnant sows; 3) Evaluate efficacy of NDV-vectored and VACV-vectored CSF vaccines in pigs. In this proposal, we plan to evaluate the immunogenicity and/or efficacy of NDV-based and VACV-COP-based PED and CSF vaccines against each pathogen in pigs. The results from these studies will provide insight on whether both vectored vaccines are able to provide protection in pigs against virus challenge, and will enhance our knowledge regarding development of effective vaccines for these economically devastating swine diseases. A previous study showed that a vaccinia recombinant virus expressing the E2 of the CSFV is able to provide protection in pigs (Koenig et al., 1995 J Virol. 69(10), 6479-86). Based on our knowledge, the NDV vector was not utilized yet to develop both PED and CSF vaccines before. If one or both vectored vaccine are demonstrated to be efficacious in pigs, one or both can be further evaluated and used as vaccine candidates and transitioned to the industry for licensure and usage to protect the US swine industry and agricultural systems. We will also be able to compare the use of a single vaccine vector platform with prime/boost approaches using two different vaccine platform vectors: NDV and VACV-COP.
Establishment and evaluation of non-spreading single-cycle replicon of RVFV in a novel RVFV challenge model in sheep
University of Texas Medical Branch PI: Tetsuro Ikegami
Kansas State University Co-PI: Juergen Richt
07/01/2012 – 01/31/2016
Abstract:
The overall goal of the project is to develop a highly pathogenic RVFV challenge model in sheep by using reverse genetics for RVFV. Our Specific Aims for FY2016 are proposed as follows:
Epizootic hemorrhagic disease (EHD): epidemiology and development of vaccine for white-tailed deer (Odocoileus virginianus)
Kansas State University PI: Igor Morozov
Kansas State University Co-PI: Juergen Richt
USDA-ARS-ABADRU Co-PI: William Wilson
USDA-ARS-ABADRU Co-PI: Scott McVey
University of California-Davis Co-PI: Jim MacLachlan
07/01/2013 – 12/31/2016
Abstract:
Evaluate the efficacy of candidate vaccines for epizootic hemorrhagic disease virus (EHDV) in white-tailed deer (Odocoileus virginianus); and better understand variation in the spatial/temporal distribution and epidemiology of EHDV infections in the United States.
Novel chimeric vaccine and delivery system for classical swine fever virus
Kansas State University PI: Ying Fang
Kansas State University Co-PI: Raymond Rowland
Kansas State University Co-PI: John Tomich
01/01/2016 – 12/31/2016
Abstract:
The overall goal of this project is to develop a viral vectored chimeric vaccine and in vivo DNA vaccine delivery system for classical swine fever virus (CSFV). Deliverables include a chimeric dual user candidate vaccine, in which modified live porcine reproductive and respiratory syndrome virus (PRRSV) is used as a vector to express the protective E2 protein of CSFV. In addition, to eliminate the need for a cold chain, a novel DNA vaccine in vivo delivery system will be established. The specific objectives for this project include 1) to construct a CSFV E2-PRRSV chimera by insertion of CSFV E2 gene into the genome of a modified live PRRSV using reverse genetics. Product will be a DNA plasmid containing a DNA-launched CSFV E2-PRRSV construct, 2) to characterize CSFV E2-PRRSV chimera and in vitro DNA delivery methods in a cell culture system. Products will be a recombinant PRRSV expressing CSFV E2 protein; and an in vitro DNA delivery reagent and method, and 3) to evaluate in vivo vaccine delivery approaches and to assess protective immunity induced by CSFV E2-PRRSV chimera using a CSFV challenge pig model. Products will be a chimeric dual user candidate vaccine and a DNA vaccine in vivo delivery system.
Efficacy study of an alphavirus replicon-based vaccine for African swine fever virus in a swine challenge model
Kansas State University PI: Natasha Gaudreault
Kansas State University Co-PI: Raymond Rowland
01/01/2016 – 12/31/2016
Abstract:
The overall goal of this project is to evaluate the efficacy of single-cycle defective alphavirus replicon-based vaccine expressing African swine fever virus (ASFV) protein 30 in a swine challenge model. This proposal provides research focused on vaccine development as well as training opportunities for students in biosafety level 3 (BSL-3) transboundary disease research, thus supporting “CEEZAD’s current priorities on emerging transboundary agricultural pathogens (i.e. vaccines, diagnostics, epidemiology/modeling and education)”. The specific objectives for this project include 1) evaluation of the efficacy of an alphavirus replicon-based ASFV vaccine, 2) characterization of the humoral and cellular immune responses following immunization and ASFV challenge in swine, and 3) provide training for students in BSL-3 and transboundary disease research.
Selection of adjuvants suitable for CSF subunit vaccines
Kansas State University PI: Jishu Shi
01/01/2016 – 12/31/2016
Abstract:
The overall goal of our research program is to develop a one dose classical swine fever (CSF) subunit vaccine that can differentiate infected from vaccinated animals. The major deliverable for this project is to identify a suitable adjuvant that can be used to formulate the CSFV E2-based subunit vaccine.
The overall objective of our research is to develop a novel one-dose CSF vaccine that not only can provide fast and long-lasting protection, but also can differentiate infected from vaccinated animals (DIVA) and be safely produced and stored in the U.S. To achieve this objective, we need to develop a superior adjuvant that can induce robust cellular and antibody response after one vaccination with CSFV E2 protein as the vaccine antigen.